Pay in 4 interest-free payments of $5.81 Learn more
Ships within 48 hours · Estimated delivery Aug 12 - Aug 17
PMID 16916826
The goal is steady, medically supervised weight loss that can actually be maintained
Based on current trial populations and how the FDA has handled semaglutide and tirzepatide approvals, expected eligibility criteria are: BMI 30 , or BMI 27 with at least one weight-related condition (type 2 diabetes, hypertension, dyslipidemia, OSA) Adults 18 and older Not pregnant or breastfeeding No history of MTC or MEN 2 Retatrutide will almost certainly launch at a high price point estimates suggest $1,200$1,500 per month at list price
It belongs to the GHRP (Growth Hormone Releasing Peptide) family but is considered one of the most selective and well-tolerated options available today
US$ 22.12
US$ 22.38
US$ 29.64
US$ 27.84
US$ 28.06
US$ 20.94
